Press Releases Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
51.3 ^USD	+2.09%		+5.02%	+7.03%

May. 15	HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	MT
May. 14	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Korro to Participate in Upcoming June Investor and Scientific Conferences	May. 30	AQ
Korro Bio : May 2024 Corporate Presentation	May. 20	PU
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference	May. 20	AQ
Korro Bio : Q1’24 Corporate Presentation	May. 14	PU
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer	May. 14	AQ
Korro Announces $70 Million Private Placement	Apr. 18	AQ
Korro to Participate in Upcoming Investor Conferences	Apr. 01	AQ
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress	Mar. 26	AQ
Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing	Mar. 13	PU
Korro to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 27	AQ
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio	Jan. 18	AQ
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	AQ
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ	23-10-06	BU
Frequency Therapeutics : Termination of Material Agreement - Form 8-K	23-09-27	PU
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results	23-08-10	BU
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ	23-07-21	BU
Korro Bio and Frequency Therapeutics Announce Merger Agreement	23-07-17	AQ
FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders	23-07-14	BU
Korro Bio and Frequency Therapeutics Announce Merger Agreement	23-07-14	BU
Frequency Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	23-06-06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Korro Bio, Inc.

Equities

KRRO

US5009461089

Press Releases

Filters